Preclinical Safety Evaluation of Oral Drug of Human Granulocyte-Macrophage Colony-Stimulating Factor Expressed in Silkworm Pupae As Bioreactor

ZHANG Yao-Zhou,JIN Yong-Feng,WU Xiang-Fu
DOI: https://doi.org/10.3969/j.issn.0257-4799.2006.02.006
2006-01-01
Abstract:We developed an oral drug of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) expressed in silkworm pupae. Our goal in this study was to determine the toxicity of oral drug of rhGM-CSF in monkeys (Macaca mulatto), rats and mice, including genetic toxicology, single-and repeat-dose systemic toxicity and reproductive toxicity. Toxicology tests showed that the maximum tolerated dose (I.v) was 3 300 μg/kg, and that the LD50 (I.v) was 2 020 μg/kg in NIH mice, and 3.660 μg/kg in SD rats respectively. Repeat-dose toxicity test of oral drug of rhGM-CSF in monkeys and rats showed that all indices (including white blood cell, red blood cell, haematoglobin content, platelet number, and hemagglutination) were normal, with the exception of glucose content in female rats, which increased significantly (P<0.001) after oral administration of the high-dose 1 250 μg·kg-1·d-1 rhGM-CSF while it reversibly was normal during recovery. It was found that rhGM-CSF oral drug showed no genotoxicity either in vitro or in vivo through the micronucleus test, CHL chromosome aberration test and Ames test. No abnormality was found in general reproductive toxicity test, and toxicity test in perinatal stage and sensitive period to teratogenic agent, which suggests little reproductive toxicity. Preclinical toxicity indicated administration of the rhGM-CSF oral drug in excess of ten times as many as clinical dosages was not associated with severe chronic toxicities and it is very safe at the range of pharmacologically functional dose. This study represents the first report of detailed toxicological evaluation of human protein drug expressed in silkworm using baculovirus expression system.
What problem does this paper attempt to address?